AVXL · Anavex Life Sciences Corp. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $4.66M | $9.96M | $9.89M | $10.45M | $11.87M | $9.73M | $8.68M | $10.28M | $11.31M | $12.07M |
| SG&A | $3.15M | $4.50M | $2.62M | $3.15M | $2.86M | $2.79M | $2.61M | $3.25M | $2.88M | $3.32M |
| Total Operating Expenses | $6.78M | $14.46M | $12.51M | $13.59M | $14.73M | $12.52M | $11.29M | $13.53M | $14.19M | $15.38M |
| D&A | - | - | - | - | - | - | - | - | - | - |
| Operating Income | ($6.78M) | ($14.46M) | ($12.51M) | ($13.59M) | ($14.73M) | ($12.52M) | ($11.29M) | ($12.46M) | ($14.19M) | ($11.72M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $18.0K | - | - | - | - | - | - | - | - | - |
| Net Income | ($5.68M) | ($13.24M) | ($11.20M) | ($12.11M) | ($12.21M) | ($10.55M) | ($8.62M) | ($11.28M) | ($13.11M) | ($12.97M) |
| EPS - Basic | ($0.06) | ($0.16) | ($0.13) | ($0.14) | ($0.14) | ($0.13) | ($0.17) | - | - | - |
| EPS - Diluted | ($0.06) | ($0.16) | ($0.13) | ($0.14) | ($0.14) | ($0.13) | ($0.17) | - | - | - |
Balance Sheet
| Line item | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $131.75M | $102.58M | $115.77M | $120.78M | $132.19M | $139.39M | $143.76M | $151.02M | $153.47M | $143.62M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $2.64M | $4.25M | $7.00M | $4.57M | $9.63M | $3.73M | $4.29M | $4.32M | $6.28M | $5.29M |
| Current Assets | - | - | - | - | - | - | - | - | - | - |
| Total Assets | $132.99M | $103.81M | $117.14M | $124.04M | $135.57M | $144.52M | $148.07M | $154.39M | $159.19M | $148.37M |
| Current Liabilities | - | - | - | - | - | - | - | - | - | - |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $6.37M | $8.95M | $17.38M | $13.13M | $15.30M | $9.56M | $12.49M | $12.53M | $14.02M | $13.25M |
| Stockholders' Equity | $126.62M | $94.87M | $99.76M | $110.92M | $120.26M | $134.96M | $135.57M | $141.85M | $145.17M | $135.12M |
| Retained Earnings | ($388.13M) | ($382.45M) | ($359.38M) | ($348.18M) | ($336.07M) | ($312.24M) | ($301.69M) | ($293.07M) | ($271.64M) | ($258.54M) |
Cash Flow
| Line item | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($7.15M) | - | - | ($12.12M) | - | - | ($7.32M) | - | - | ($5.79M) |
| Investing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | $36.32M | - | - | $708.0K | - | - | $59.0K | - | - | $258.2K |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -4.3% | -12.8% | -9.6% | -9.8% | -9.0% | -7.3% | -5.8% | -7.3% | -8.2% | -8.7% |
| Return on equity | -4.5% | -14.0% | -11.2% | -10.9% | -10.2% | -7.8% | -6.4% | -8.0% | -9.0% | -9.6% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | - | - | - | - | - | - | - | - | - | - |
| Quick ratio | - | - | - | - | - | - | - | - | - | - |
| Cash ratio | - | - | - | - | - | - | - | - | - | - |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.05 | 1.09 | 1.17 | 1.12 | 1.13 | 1.07 | 1.09 | 1.09 | 1.10 | 1.10 |
| Liabilities / Assets | 0.05 | 0.09 | 0.15 | 0.11 | 0.11 | 0.07 | 0.08 | 0.08 | 0.09 | 0.09 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 2.5x | 8.0x | 7.3x | 8.2x | 4.0x | 3.1x | 5.4x | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 50.1% | 1.8% | 0.0% | -20.4% | -18.2% | 11.8% | 3.7% | -1.5% | -36.3% | -8.0% |
| Net income growth (YoY) | 53.1% | -8.4% | -6.2% | -40.5% | -8.3% | 19.5% | 33.5% | 8.8% | -25.6% | -19.2% |
| EPS growth (YoY) | 57.1% | -14.3% | 0.0% | 17.6% | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 14.2% | -21.1% | -26.1% | -18.2% | -15.2% | -7.0% | 0.3% | -0.4% | -4.6% | -7.7% |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing ANAVEX LIFE SCIENCES CORP. against the 5 most active filers in the same SIC group.